Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MLL-menin and FLT3 inhibitors team up for AML.

Blood - 19 Nov 2020

Perl Alexander E

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to Leukemia, Myeloid, Acute
Share to Mutation
Share to Myeloid-Lymphoid Leukemia Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Transcription Factors

Source

Identifiers

PMID: 33211832
DOI: 10.1182/blood.2020007671

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MLL-menin and FLT3 inhibitors team up for AML.PMID 33211832Read ↗

FLT3 Inhibitors in AML: Are We There Yet?Semantic proximity Read ↗

New strategies to treat AML: novel insights into AML survival pathways and combination therapiesSemantic proximity Read ↗

Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.Semantic proximity Read ↗

Targeting IDH: the next big thing in AML.Semantic proximity Read ↗

An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape.Semantic proximity Read ↗

Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.Semantic proximity Read ↗

First new drug approval for AML in 15 years.Semantic proximity Read ↗

Advances in the pharmacological management of acute myeloid leukemia in adults.Semantic proximity Read ↗

Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity Read ↗

Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies.Semantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapiesSemantic proximity Read ↗

Frontline treatment of AML in adults.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.